 Library
of Slides and Posters |
|
|
Steady
State Evaluation of Two Extended Release (XR) Nevirapine
(NVP) Tablets 400 mg QD Compared with
Immediate Release (IR) NVP Tablets 200 mg BID in
HIV-1 Infected Patients
A. Quinson
and others. ICAAC 2009.
|
 |
Early
Virological and Immunological Response is Comparable
between Nevirapine and
RTV-boosted Atazanavir: An ARTEN Sub-analysis
J Soriano and
others. ICAAC 2009.
|
|
Pharmacokinetic
interaction between etravirine
and fluconazole or voriconazole in HIV-negative
volunteers
M Schöller-Gyüre
and others. ICAAC 2009. |
|
|
GRACE
(Gender, Race And Clinical Experience): Etravirine
(ETR) Subgroup Analysis at Week 48
S Hodder and others. ICAAC
2009. |
|
|
GRACE
(Gender, Race And Clinical Experience):
Outcomes by Race at Week 48
K Smith and others. ICAAC
2009. |
|
|
Bioavailability
and food effect of darunavir
following administration of an oral suspension
V Sekar and others. ICAAC
2009. |
|
|
Pharmacokinetic
interaction between darunavir
in combination with low-dose
ritonavir and buprenorphine/naloxone
V Sekar and others. ICAAC
2009. |
|
|
Insertions
at positions 33 and 35 of the HIV-1 protease: prevalence
and role in virologic failure in darunavir-treated
patients
S De Meyer and others. ICAAC
2009. |
|
|
Pharmacokinetic
interaction between etravirine
and lopinavir/ritonavir
M Schöller-Gyüre and others.
ICAAC 2009. |
|
|
Pharmacokinetic
Boosting of Atazanavir
with the Pharmacoenhancer
GS-9350 versus Ritonavir
S Ramanathan and others. ICAAC
2009. |
|
|
Effect
of Food on Pharmacokinetics of Elvitegravir,
Emtricitabine, Tenofovir DF and the Pharmacoenhancer
GS-9350 as a
Fixed- Dose Combination Tablet
P German and others. ICAAC
2009. |
|
|
HIV
Testing Among Patients Screened, Diagnosed, or Treated
for Sexually Transmitted
Diseases
J Chen and others. ICAAC 2009. |
|
|
Improvement
in Fasting Lipids but Minimal Recovery of Limb Fat
Were Seen 96 Weeks After Switching from Lamivudine/Zidovudine
Plus Efavirenz to Fixed-Dose Efavirenz/Emtricitabine/Tenofovir
DF in HIV-Infected Patients
E DeJesus and others. ICAAC
2009. |
|
|
Lack
of a Clinically Important Effect of Rifabutin
(RFB) on Raltegravir (RAL) Pharmacokinetics
D Brainard and others. ICAAC
2009. |
|
|
Metabolic
Profiles and Body Composition Changes in Treatment-Naïve
HIV-Infected Patients Treated with Raltegravir
400 mg bid-based vs. Efavirenz
600 mg qhs-based Combination Therapy: 48-Week Data
E DeJesus and others. ICAAC
2009. |
|
|
HIV
Integrase Inhibitors Do Not Exert A Post-Antibiotic
Effect Despite Slow Dissociation From IN-DNA Complexes
In Vitro
R Hluhanich and others. ICAAC
2009. |
|
|
Raltegravir
Demonstrates Durable Efficacy Through 96 Weeks:
Results from STARTMRK, A Phase III Study of Raltegravir-based
vs. Efavirenz-based Therapy in Treatment-Naïve
HIV+ Patients
J Lennox and others. ICAAC
2009. |
|
|
TDF-containing
Antiretroviral Regimens in Pregnancy:
Findings from the Antiretroviral Pregnancy Registry
K Squires and others. ICAAC
2009. |
|
|
Vicriviroc
Long-term Safety and Efficacy: 96-Week Results from
the VICTOR-E1 Study
M McCarthy and others. ICAAC
2009. |
|
|
Clonal
Analysis of the gp120 V3 Loop from Clinical Isolates
Displaying Phenotypic Resistance to Vicriviroc
P McNicholas and others. ICAAC
2009. |
|
|
Assessment
of Pharmacokinetic and Safety Interactions Between
Vicriviroc and
CYP3A4 Substrates, Inhibitors,
and Inducers
C Kasserra and others. ICAAC
2009. |
|
|
Discovery
of GS-9350:
A Novel Pharmacoenhancer without Anti-HIV Activity
L Xu and others. ICAAC 2009. |
HIV
and AIDS Articles |
|
|
HIV
Maturation Inhibitor Bevirimat Demonstrates
Promising Safety and Efficacy in Patients with Responsive
HIV Genotype |
|
|
Investigational
Pharmaco-enhancer GS-9350
Equals Ritonavir
(Norvir) as a Booster for Atazanavir
(Reyataz) |
|
|
Raltegravir
(Isentress) Demonstrates Safety and Antiviral
Efficacy at 24 Weeks in Adolescents with HIV |
|
|
Raltegravir
(Isentress) plus Atazanavir (Reyataz)
Maintenance Therapy Appears Safe and Effective in
Small Study |
|
|
Short-term
Enfuvirtide (Fuzeon)
May Promote Long-term CD4 Cell Recovery in Patients
Who Start Treatment Late |
|
|
People
Who Decline Routine HIV
Testing Are More Likely to Be Positive;
Written Consent Requirement May Discourage Testing |
|
|
Monoclonal
Antibody PRO 140 Demonstrates Good Tolerability
and Potent Activity against CCR5-tropic HIV |
|
|
Variations
in "SEVI" Semen
Component May Help Explain Racial/ethnic Differences
in HIV Infection Rates |
|
|
Effective
Antiretroviral Therapy Leads to Improved Lung
Function in People with HIV |
|
|
Early
Studies Demonstrate Potent Activity and Safety of
Experimental Integrase
Inhibitor S/GSK1265744 |
|
|
Once
Daily Raltegravir (Isentress)
Shows Promise in Pilot Study |
|
|
Nevirapine
(Viramune) and Boosted Atazanavir (Reyataz)
Produce Comparable Early Virological and Immunological
Response |
|
|
Nutritional
Formula Reduces CD4 Cell Decline in HIV
Positive People Not Yet Taking Antiretroviral Therapy |
|
|
New
Injectable Drug Peramivir Is as Effective
as Oseltamivir (Tamiflu) for Seasonal Influenza |
|
|
IL-7
Improves CD4 and CD8 T-Cell Recovery among HIV Patients
on Suppressive Antiretroviral Therapy |
|
|
GRACE
Trial shows Women Respond as well as
Men to Etravirine (Intelence),
but Blacks May Have Poorer Outcomes than Whites |
|
|
CCR5
Antagonist Vicriviroc
Demonstrates Long-Term Safety and Efficacy at 96
Weeks |
|
|
At
96 Weeks, Raltegravir (Isentress)
Is as Effective as Efavirenz (Sustiva) in Suppressing
HIV Viral Load and Improving Immune Function |
|
|
Tobacco
and Marijuana May Significantly Lower Atazanavir
(Reyataz) Blood Levels |
|
|
Antiretroviral
Pregnancy Registry Indicates Use of Tenofovir
(Viread) by Pregnant Women Does Not Raise
Risk of Birth Defects |
Hepatitis
B or C Articles |
|
|
High-dose
Hepatitis B Vaccination
May Protect HIV Positive People Who Do Not Respond
to a Standard Dose |
|
|
HCV
Re-infection Is Common, Mainly Due to
Injection Drug Use, among Canadian Prisoners Treated
for Hepatitis C |
|
|
HCV
Viral Load Decline during the First 24 Hours of
Interferon-based Therapy
Predicts Long-term Outcomes in HIV-HCV Coinfected
Patients |
|
|
Experimental
Agent ATI-0810 Appears to Have Novel
Mechanism of Action against Hepatitis C Virus |
HIV-HCV
or HIV-HBV Coinfection Articles |
|
|
Population-based
Surveillance of Acute Hepatitis
B and C Infection among Men Who Have
Sex with Men |
|
|
HCV
Viral Load Decline during the First 24 Hours of
Interferon-based Therapy Predicts Long-term Outcomes
in HIV-HCV Coinfected Patients |
|
HIV
Positive People May Respond Poorly to Pegylated
Interferon without Ribavirin for Acute
Hepatitis C |
|
|
Resistance
to Hepatitis B Drugs is Common among HIV/HBV Coinfected
Patients Receiving Lamivudine-containing
ART without Tenofovir (Viread) |
| |
 |
